Español
Reflexión crítica sobre la distribución de vacunas para la COVID19 en el mundo
DOI:
https://doi.org/10.31052/1853.1180.v27.n1.32772Keywords:
COVID19, Pandemic, Vaccines, Equity, PatentsAbstract
The SARS-CoV-2 pandemic is hitting the world. The massive interconnectivity, airborne transmission, presymptomatic contagiousness and the absence of pharmacological treatments contributed to its wide distribution. Cases skyrocketed around the world. The tools available were the classic non-pharmacological interventions of epidemiology. Some countries used them effectively and managed to control the pandemic. The rest go through second or third waves of cases. The pandemic deepened previous inequalities in the world. Less than a year after the start of the pandemic, the arrival of vaccines raised new hopes. However, the shortage of doses and inequities in their distribution triggered controversies. The goal of herd immunity by vaccine is unattainable. Immunizing risk groups to reduce deaths only seems possible in a few countries. A critical reflection was carried out on the distribution of vaccines in the world.
Downloads
References
Who.int. 2020 [cited 2022 Jan 12]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200401-sitrep-72-covid-19.pdf?sfvrsn=3dd8971b_2.
Samet JM, Prather K, Benjamin G, Lakdawala S, Lowe J-M, Reingold A, et al. Airborne transmission of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2): What we know. Clin Infect Dis. 2021;73(10):1924–6.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–207.
Wei WE, Li Z, Chiew CJ. Presymptomatic Transmission of SARS-CoV-2—Singapore, January 23–March 16, 2020. Morbidity and Mortality Weekly Report. 2020;69(14):411.
Lam S, Lombardi A, Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. Eur J Pharmacol. 2020; 886(173451):173451.
Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020; 584(7820):257–61.
De Candia L, Bulla V, Cordone R, Quignard M, Montaner A, Kohen J. Viejas herramientas para nuevos problemas: Intervenciones no farmacologías para afrontar la pandemia del COVID-19. Rev. argent. salud publica 2021; 13(Suplemento COVID-19): 1-7.
Mortality analyses [Internet]. Johns Hopkins Coronavirus Resource Center. [cited 2022 Jan 12]. Available from: https://coronavirus.jhu.edu/data/mortality.
Heaton PM. The covid-19 vaccine-development multiverse. N Engl J Med. 2020;383(20):1986–8.
Golob JL, Lugogo N, Lauring AS, Lok AS. SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight. 2021 May 10;6(9):e149187.
Bv S. The arrival of Sputnik V. Lancet Infect Dis. 2020;20(10):1128.
Mahase E. Covid-19: What do we know about the late stage vaccine candidates? BMJ. 2020;371:m4576.
Lineamientos técnicos y Manual del vacunador [Internet]. Gob.ar. 2021 [citado el 07 de abril de 2021]. Disponible en: https://www.argentina.gob.ar/coronavirus/vacuna/equipos-salud/lineamientos-manual-vacunador.
Kirby T. New variant of SARS-CoV-2 in UK causes surge of COVID-19. Lancet Respir Med. 2021;9(2):e20–1.
Kirby T. When should the UK lift its lockdown? Lancet Respir Med. 2021;9(4):e44–5.
Kupferschmidt K. Fast-spreading UK virus variant raises alarms. Science. 2021; 9-10.
Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021;27(4):622–5.
Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1885–98.
Sabino EC, Buss LF, Carvalho MPS, Prete CA Jr, Crispim MAE, Fraiji NA, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet. 2021;397(10273):452–5.
Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2022;22(2):183–95.
Petersen E, Ntoumi F, Hui DS, Abubakar A, Kramer LD, Obiero C, et al. Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int J Infect Dis. 2022;114:268-272.
Tan SY, Ponstein N. Jonas Salk (1914-1995): A vaccine against polio. Singapore Med J. 2019;60(1):9–10.
Fujimura SF. La vacuna contra la polio, “Gracias Dr. Salk”. Perspectivas de Salud. Organización Panamericana de la Salud. 2005; 10 (2).
Saldías E. Centenario del natalicio del Dr. Albert B Sabin. Rev Chil Infect. 2006;23(4):368–9.
Shampo MA, Kyle RA. Jonas E. Salk discoverer of a vaccine against poliomyelitis. Mayo Clin Proc 1998, 73 (12): 1176.
Tan SY, Ponstein N. Jonas Salk (1914-1995): A vaccine against polio. Singapore Med J. 2019;60(1):9–10.
Ra N, Keusch GT. Salud Mundial: Lecciones de la Ley Bayh-Dole [Internet]. Pipra.org. [cited 2022 Mar 9]. Available from: https://pipra.org/publications-files/F1_8_Nuget.pdf.
Mascola JR, Graham BS, Fauci AS. SARS-CoV-2 viral variants-tackling a moving target. JAMA. 2021;325(13):1261–2.
Goldstein A. Failure to achieve global vaccine equity will have dire consequences. BMJ. 2021;372:n712.
Understanding vaccination progress by country [Internet]. Johns Hopkins Coronavirus Resource Center. [cited 2022 Jan 12]. Available from: https://coronavirus.jhu.edu/vaccines/international.
TÉLAM. Angustia en el mundo por las demoras en la producción y entrega de las vacunas contra el coronavirus [Internet]. Com.ar. [cited 2022 Jan 12]. Available from: https://www.telam.com.ar/notas/202101/542454-angustia-mundo-demora-vacunas-coronavirus.html.
March 8 th -prepared for vaccine supply & production summit COVID-19 vaccine production [Internet]. Ifpma.org. [cited 2022 Jan 12]. Available from: https://www.ifpma.org/wp-content/uploads/2021/03/Airfinity_global_summit_master_final.pdf
Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):947–53.
La OMS critica el egoísmo de los países ricos y las farmacéuticas frente a las vacunas del COVID-19 [Internet]. Noticias ONU. 2021 [cited 2022 Jan 12]. Available from: https://news.un.org/es/story/2021/01/1486742.
Goldstein A. Failure to achieve global vaccine equity will have dire consequences. BMJ. 2021;372:n712.
Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):947–53.
Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–100.
Burki TK. Fourth dose of COVID-19 vaccines in Israel. Lancet Respir Med. 2022;10(2):e19.
Minsal.cl. [cited 2022 jan 12]. Available from: https://www.minsal.cl/covid-19-gobierno-anuncia-que-este-proximo-lunes-comienza-el-proceso-de-vacunacion-de-cuarta-dosis/.
Alocución de apertura del Director General de la OMS en la rueda de prensa sobre la COVID-19 del 6 de enero de 2022 [Internet]. Who.int. [cited 2022 Jan 12]. Available from: https://www.who.int/es/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---6-january-2022.
COVAX: colaboración para un acceso equitativo mundial a las vacunas contra la COVID-19 [Internet]. Who.int. [cited 2022 Jan 12]. Available from: https://www.who.int/es/initiatives/act-accelerator/covax.
McAdams D, McDade KK, Ogbuoji O, Johnson M, Dixit S, Yamey G. Incentivising wealthy nations to participate in the COVID-19 Vaccine Global Access Facility (COVAX): a game theory perspective. BMJ Glob Health. 2020;5(11):e003627.
Nytimes.com. [cited 2022 Jan 12]. Available from: https://www.nytimes.com/2021/01/12/opinion/world-covid-vaccines.html.
COVAX informa a los participantes de los retrasos en la entrega de vacunas del Serum institute de la India (sii) y AstraZeneca [Internet]. Who.int. [cited 2022 Jan 12]. Available from: https://www.who.int/es/news/item/25-03-2021-covax-updates-participants-on-delivery-delays-for-vaccines-from-serum-institute-of-india-(sii)-and-astrazeneca.
Usher AD. “A beautiful idea: how COVAX has fallen short.” Lancet (London, England) vol. 397,10292 (2021): 2322-2325.
Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020 Apr 14;52(4):583-589.
Edridge A, Kaczorowska J, Hoste A, Bakker M, Klein M, Loens, K, et al. Seasonal coronavirus protective immunity is short-lasting. Nature medicine 2021, 26(11): 1691–93.
BOLETIN OFICIAL REPUBLICA ARGENTINA - MEDIDAS GENERALES DE PREVENCIÓN - Decisión Administrativa 1198/2021 [Internet]. Gob.ar. [cited 2022 Jan 19]. Available from: https://www.boletinoficial.gob.ar/detalleAviso/primera/254239/20211213.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
Mallapaty S. Can COVID vaccines stop transmission? Scientists race to find answers. Nature. 2021. doi: 10.1038/d41586-021-00450-z. Epub ahead of print.
Tiyo BT, Schmitz GJH, Ortega MM, da Silva LT, de Almeida A, Oshiro TM, et al. What happens to the immune system after vaccination or recovery from COVID-19? Life (Basel). 2021;11(11):1152.
Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467-484.e15.
De Candia LF, Santucci N, Alloatti A, Barchiesi J, Bergonzi M, Blázquez F, et al. Efecto de la vacunación sobre la transmisión intradomiciliaria del SARS-COV-2, provincia de Santa Fe, Argentina, 2021. Rev. argent. salud publica 2021; 13(Suplemento COVID-19): 1-6.
Fernández L, Shorett P. Lessons in equity from the front lines of COVID-19 vaccination. JAMA Health Forum. 2021;2(4):e210612.
Barsky BA, Reinhart E, Farmer P, Keshavjee S. Vaccination plus decarceration - stopping covid-19 in jails and prisons. N Engl J Med. 2021;384(17):1583–5.
Quinn SC, Andrasik MP. Addressing Vaccine Hesitancy in BIPOC Communities - Toward Trustworthiness, Partnership, and Reciprocity. N Engl J Med. 2021;385(2):97.
Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 vaccinations [published correction appears in Nat Hum Behav. 2021 Jun 17]. Nat Hum Behav. 2021;5(7):947-953.
Hotez P. COVID vaccines: time to confront anti-vax aggression. Nature. 2021; 592, 661.
Los líderes mundiales piden un nuevo tratado internacional para mejorar la respuesta a una pandemia [Internet]. Noticias ONU. 2021 [cited 2022 Jan 12]. Available from: https://news.un.org/es/story/2021/03/1490312.
La APDH solicitó con urgencia a Naciones Unidas que se liberen las patentes de las vacunas por el COVID 19 [Internet]. APDH. [cited 2022 Jan 12]. Available from: https://apdh.org.ar/declaraciones/onu-liberen-patentes-vacunas.
Katz IT, Weintraub R, Bekker LG, Brandt AM. From Vaccine Nationalism to Vaccine Equity - Finding a Path Forward. N Engl J Med. 2021;384(14):1281-1283.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Escuela de Salud Pública y Ambiente. Facultad de Ciencias Médicas. Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License which allows the work to be copied, distributed, exhibited and interpreted as long as it is not done for commercial purposes.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication process. (See The Effect of Open Access). (See The Effect of Open Access).
How to Cite
